JNJ Stock Analysis: Johnson & Johnson | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 631.586m USD | 12M Return: 57.6% | US4781601046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.82B
EPS Trend: 32.9%
Qual. Beats: 0
Rev. Trend: 94.3%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Johnson & Johnson (NYSE: JNJ) is a global healthcare company founded in 1886 and headquartered in New Brunswick, New Jersey. It operates through two main segments: Innovative Medicine, which focuses on prescription pharmaceuticals across therapeutic areas including oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolic diseases; and MedTech, which provides medical devices and technologies for surgery, orthopedics, cardiovascular care, and vision. MedTech products serve professional use in hospitals, clinics, and physicians offices, spanning joint reconstruction, trauma, spine, sports injuries, open and robotic surgical procedures, wound closure, breast aesthetics, and contact lenses under brands such as ACUVUE and TECNIS. Distribution channels include wholesalers, retailers, distributors, hospitals, and healthcare professionals.
The company is classified within the GICS Health Care sector and is one of the largest U.S. pharmaceutical issuers by market capitalization, listed on the NYSE since 1944. Its dual-segment structure combines the higher-margin, patent-driven economics of branded pharmaceuticals with the more diversified, equipment- and consumables-based revenue model typical of large medical device businesses.
- Talc litigation reserves and settlement costs pressure earnings outlook
- Stelara biosimilar competition erodes Innovative Medicine segment revenue
- MedTech cardiovascular and vision portfolio growth offsets surgical weakness
| Net Income: 21.0b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.82 > 1.0 |
| NWC/Revenue: 4.98% < 20% (prev 0.35%; Δ 4.63% < -1%) |
| CFO/TA 0.12 > 3% & CFO 23.7b > Net Income 21.0b |
| Net Debt (28.3b) to EBITDA (33.7b): 0.84 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.44b) vs 12m ago 0.87% < -2% |
| Gross Margin: 70.45% > 18% (prev 67.92%; Δ 2.54% > 0.5%) |
| Asset Turnover: 49.65% > 50% (prev 46.86%; Δ 2.79% > 0%) |
| Interest Coverage Ratio: 25.67 > 6 (EBIT TTM 26.0b / Interest Expense TTM 1.01b) |
| A: 0.02 (Total Current Assets 59.8b - Total Current Liabilities 54.9b) / Total Assets 201b |
| B: 0.85 (Retained Earnings 172b / Total Assets 201b) |
| C: 0.13 (EBIT TTM 26.0b / Avg Total Assets 197b) |
| D: 0.73 (Book Value of Equity 85.0b / Total Liabilities 116b) |
| Altman-Z'' = 4.60 = AA |
| DSRI: 0.99 (Receivables 19.0b/17.8b, Revenue 97.9b/90.6b) |
| GMI: 0.96 (GM 67.92% / 70.45%) |
| AQI: 0.97 (AQ_t 0.59 / AQ_t-1 0.60) |
| SGI: 1.08 (Revenue 97.9b / 90.6b) |
| TATA: -0.01 (NI 21.0b - CFO 23.7b) / TA 201b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of August 20, 2026, the stock is trading at USD 273.41 with a total of 6,264,427 shares traded. Over the past week, the price has changed by +4.81%, over one month by +9.88%, over three months by +19.57% and over the past year by +57.63%.
Current recommended Stop Loss: 265.50 (which is 2.9% or 1.3 ATR below the current price).
Johnson & Johnson has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold JNJ.
- StrongBuy: 7
- Buy: 4
- Hold: 13
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 272.5 | -0.3% |
P/E Trailing = 30.2983
P/E Forward = 22.4719
P/S = 6.4494
P/B = 7.4253
P/EG = 4.3217
Revenue TTM = 97.9b USD
EBIT TTM = 26.0b USD
EBITDA TTM = 33.7b USD
Long Term Debt = 37.3b USD (from longTermDebt, last quarter)
Short Term Debt = 11.7b USD (from shortTermDebt, last quarter)
Debt = 49.0b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 28.3b USD (calculated: Debt 49.0b - CCE 20.8b)
Enterprise Value = 660b USD (632b + Debt 49.0b - CCE 20.8b)
Interest Coverage Ratio = 25.67 (Ebit TTM 26.0b / Interest Expense TTM 1.01b)
EV/FCF = 35.27x (Enterprise Value 660b / FCF TTM 18.7b)
FCF Yield = 2.84% (FCF TTM 18.7b / Enterprise Value 660b)
FCF Margin = 19.10% (FCF TTM 18.7b / Revenue TTM 97.9b)
Net Margin = 21.48% (Net Income TTM 21.0b / Revenue TTM 97.9b)
Gross Margin = 70.45% ((Revenue TTM 97.9b - Cost of Revenue TTM 28.9b) / Revenue TTM)
Gross Margin QoQ = 73.11% (prev 71.49%)
Tobins Q-Ratio = 3.28 (Enterprise Value 660b / Total Assets 201b)
Interest Expense / Debt = 2.06% (Interest Expense 1.01b / Debt 49.0b)
Taxrate = 16.51% (4.16b / 25.2b)
NOPAT = 21.7b (EBIT 26.0b * (1 - 16.51%))
Current Ratio = 1.09 (Total Current Assets 59.8b / Total Current Liabilities 54.9b)
Debt / Equity = 0.58 (Debt 49.0b / totalStockholderEquity, last quarter 85.0b)
Debt / EBITDA = 0.84 (Net Debt 28.3b / EBITDA 33.7b)
Debt / FCF = 1.51 (Net Debt 28.3b / FCF TTM 18.7b)
Total Stockholder Equity = 81.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.67% (Net Income 21.0b / Total Assets 201b)
RoE = 25.74% (Net Income TTM 21.0b / Total Stockholder Equity 81.7b)
RoCE = 21.82% (EBIT 26.0b / Capital Employed (Equity 81.7b + L.T.Debt 37.3b))
RoIC = 14.18% (NOPAT 21.7b / Invested Capital 153b)
WACC = 4.42% (E(632b)/V(681b) * Re(4.63%) + D(49.0b)/V(681b) * Rd(2.06%) * (1-Tc(0.17)))
Discount Rate = 4.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 66.48 | Cagr: 0.18%
[DCF] Terminal Value 77.81% ; FCFF base≈17.8b ; Y1≈20.2b ; Y5≈29.1b
[DCF] Fair Price = 170.4 (EV 439b - Net Debt 28.3b = Equity 411b / Shares 2.41b; r=8.35% [WACC [floored]]; 5y FCF grow 14.00% → 2.50% )
EPS Correlation: 32.91 | EPS CAGR: 1.05% | SUE: 0.75 | # QB: 0
Revenue Correlation: 94.35 | Revenue CAGR: 4.92% | SUE: 0.98 | # QB: 3
EPS current Quarter (2026-09-30): EPS=2.42 | Chg30d=-19.80% | Revisions=+35% | Analysts=4
EPS current Year (2026-12-31): EPS=11.05 | Chg30d=-4.57% | Revisions=+88% | GrowthEPS=+2.4% | GrowthRev=+7.4%
EPS next Year (2027-12-31): EPS=12.31 | Chg30d=-3.43% | Revisions=+54% | GrowthEPS=+11.3% | GrowthRev=+7.6%
[Analyst] Revisions Ratio: +68% (up=48, down=8)